EF Hutton initiated coverage of Artelo Biosciences with a Buy rating and $6 price target Artelo is an emerging biotechnology company focused on cachexia and chemotherapy-induced peripheral neuropathy, the analyst tells investors in a research note. The firm says the company is early in its growth phase, and raising capital will be mission-critical to realize the next series of value inflection points.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue